C4 Therapeutics Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker.
Neuron23 Inc. has identified non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of neurological disorders.
Hepatocellular carcinoma (HCC) is characterized by a high rate of neovascularization, giving tumoral cells access to nutrients and contributing to disease progression and metastasis.
CD38 is the main NAD+-hydrolyzing enzyme, and it also catabolizes nicotinamide mononucleotide (NMN) and other extracellular NAD+ precursors prior to their intracellular transport for NAD+ biosynthesis.
Researchers from the University of Jeddah and Cairo University have reported the discovery of novel anticancer candidates with efficacy in models of colorectal carcinoma.
RSS
